Brenda Weigel, MD, MSc

Dr. Brenda Weigel is currently the Director of the Division of Pediatric Hematology/Oncology. She is a professor cross-appointed at the University of Minnesota's Cancer Center and the Department of Pediatrics, and the recipient of the Lehman/Children’s Cancer Research Fund Endowed Chair in Pediatric Cancer. She is also the Co-Director of the Sarcoma Program for the Masonic Cancer Center, and an Associate Director of the Cancer Experimental Therapeutics Initiative for the Masonic Cancer Center.

Dr. Weigel received her medical degree from MacMaster University in Hamilton, Ontario, and did her residency in Pediatrics at the University of Western Ontario. She came to the University of Minnesota in 1996 to do a Fellowship in Pediatric Hematology/Oncology and Bone Marrow Transplant. During her four-year fellowship, Dr. Weigel worked in the lab of Dr. Bruce Blazar and developed a murine model of rhabdomyosarcoma.

• Minnesota Monthly "Top Doctors" (2016-2019, 2021)
• Minneapolis - St. Paul "Top Doctors" (2012-2017, 2020, 2021) 
• Best Doctors in America® (2009-2013)
• Appointed member of AACR Pediatric Oncology Task Force (2009)
• Advisory Board for Pediatric Sarcoma, American Society of Clinical Oncology (2008)
• NIH/NCI Pediatric Pre-clinical Testing Program, COG Disease Committee Liaison Advisory Council (2006)
• Butterfly Award, Children’s Cancer Research Fund (2006)
• Alexander Charles Jundt Research Award (2005)
• Lehman/Children's Cancer Research Fund, Endowed Chair in Pediatric Cancer (2004)
• University Pediatrics Foundation Scholar Award, University of Minnesota (2003)
• Translational Research Award, Children's Oncology Group (2002)
• Young Investigator Award, Children's Oncology Group (2002-2003)
• Young Investigator Award, American Society of Clinical Oncology (1999-2001)
• Chief Fellow, Pediatric Hematology/Oncology,University of Minnesota (1998-2000)

Chair, Developmental Therapeutics Committee, Children's Oncology Group (COG)

Dr. Weigel’s translational research interests are centered in her extensive involvement with the Children’s Oncology Group (COG). Her responsibilities with the COG include:

• Chair, Developmental Therapeutics
• Co-chair for New High Risk Rhabdomyosarcoma Study
• Chair, Phase II Study of IGFR Antibody
• Chair, High Risk Rhabdomyosarcoma Study